This inventor holds 2 USPTO granted patents and 1 published patent application and 1 EPO patent. Top assignees: Anacardio Ab, Helsinn Healthcare Sa. Active years: 2026.
Company Filing History:
2 out of 2 
2 out of 70 
Years Active: 2026
Title: Lars Lund - Innovator in Cardiovascular Treatments
Introduction: Lars Lund is an inventor based in Stockholm, Sweden. He has made significant contributions to the field of cardiovascular treatments through his innovative research. Although he currently holds no granted patents, his work has the potential to impact the medical community significantly.
Latest Patent Applications: One of Lars Lund's notable patent applications is titled "Piperidine Urea Derivatives for Use as Inotropic Agents." This invention concerns the use of compounds represented by a specific formula as inotropic agents. The compounds, including 1-[(1S)-1-(2,3-dichloro-4-methoxyphenyl)ethyl]-3-methyl-3-[(4R)-1-methyl-3,3-dimethyl-4-piperidyl]-urea and its hydrochloride salt, have shown significant inotropic activity on cardiomyocytes from both normal and myocardial infarction-induced heart failure animal models. This makes them useful for treating cardiovascular patients in need. Unlike known inotropic agents, these compounds effectively enhance cardiomyocyte contractility without influencing calcium mobilization. Consequently, they are free from adverse effects caused by increased calcium concentrations, such as increased oxygen demand, tachycardia, arrhythmia, and ischemia. Overall, this invention presents a new, safe, and effective inotropic treatment option.
Conclusion: Lars Lund's innovative work in the field of cardiovascular treatments showcases his dedication to improving patient care. His research on piperidine urea derivatives highlights the potential for safer inotropic agents in medical applications.